Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Antiflu-Des is an over-the-counter (OTC) combination medication developed and manufactured by the Mexican pharmaceutical company Chinoin. It is indicated for the symptomatic relief of the common cold and influenza, targeting symptoms such as fever, nasal congestion, sneezing, and body aches. The formulation typically consists of three active ingredients: acetaminophen (paracetamol), which provides analgesic and antipyretic effects by inhibiting prostaglandin synthesis in the central nervous system; chlorphenamine maleate, a first-generation antihistamine that reduces allergic-like respiratory symptoms by antagonizing H1 receptors; and amantadine hydrochloride, an antiviral agent that inhibits the M2 ion channel of the influenza A virus to prevent viral uncoating and replication. It is widely available in Mexico and other Latin American markets, primarily in capsule form for adults.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Antiflu-Des.